Royalty Pharma plc (RPRX) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
RPRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RPRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 100.0% | 65.6% | 32.4% |
| 2024 | 100.0% | 57.1% | 37.9% |
| 2023 | 100.0% | 63.4% | 48.2% |
| 2022 | 100.0% | 13.7% | 1.9% |
| 2021 | 100.0% | 62.5% | 27.1% |
Download Data
Export RPRX earnings history in CSV or JSON format
Free sign-in required to download data
Royalty Pharma plc (RPRX) Earnings Overview
As of May 8, 2026, Royalty Pharma plc (RPRX) reported trailing twelve-month net income of $828M, reflecting -5.8% year-over-year growth. The company earned $1.80 per diluted share over the past four quarters, with a net profit margin of 32.4%.
Looking at the long-term picture, RPRX's 5-year EPS compound annual growth rate (CAGR) stands at +7.1%, showing solid earnings momentum. The company achieved its highest annual net income of $2.35B in fiscal 2019.
Royalty Pharma plc maintains industry-leading profitability with a gross margin of 100.0%, operating margin of 65.6%, and net margin of 32.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), OR ($207M net income, 74.3% margin), WPM ($1.48B net income, 63.6% margin), RPRX has outperformed on profitability metrics. Compare RPRX vs RCUS →
RPRX Earnings vs Peers
Earnings metrics vs comparable public companies
RPRX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $771M | -10.2% | $1.56B | $1.80 | 32.4% | 65.6% |
| 2024 | $859M | -24.3% | $1.29B | $1.91 | 37.9% | 57.1% |
| 2023 | $1.13B | +2549.5% | $1.49B | $2.53 | 48.2% | 63.4% |
| 2022 | $43M | -93.1% | $307M | $0.10 | 1.9% | 13.7% |
| 2021 | $620M | -36.4% | $1.43B | $1.49 | 27.1% | 62.5% |
| 2020 | $975M | -58.5% | $1.60B | $1.28 | 45.9% | 75.2% |
| 2019 | $2.35B | +70.5% | $2.62B | $6.63 | 129.4% | 144.6% |
| 2018 | $1.38B | +13.9% | $1.36B | $3.89 | 76.8% | 76.0% |
| 2017 | $1.21B | - | $940M | $3.42 | 75.7% | 58.8% |
Full RPRX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See RPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRPRX — Frequently Asked Questions
Quick answers to the most common questions about buying RPRX stock.
Is RPRX growing earnings?
RPRX EPS fell to $1.80, with earnings declining -5.8%. This contrasts with the 5-year CAGR of +7.1%. TTM net income dropped to $828M.
What are RPRX's profit margins?
Royalty Pharma plc net margin is +32.4%, with operating margin at +65.6%. Above-average margins indicate pricing power.
How consistent are RPRX's earnings?
RPRX earnings data spans 2017-2025. The declining earnings trend is -5.8% YoY. Historical data enables comparison across business cycles.